Skip to main content
. 2023 Mar 15;133(6):e164354. doi: 10.1172/JCI164354

Figure 6. Decreased TRIM21 expression in human cancers and low TRIM21 expression is correlated with poor prognosis in patients with mutp53 cancers.

Figure 6

(A and B) TRIM21 protein levels were frequently decreased in 2 cohorts of colorectal tumor specimens (A) and a cohort of breast tumor specimens (B) compared with their matched adjacent nontumor tissues in TMAs, as analyzed by IHC staining. Left: Representative IHC staining images of TRIM21 in tumors (T) and their matched adjacent nontumor tissues (NT). Scale bar: 60 μm. Middle: TRIM21 protein levels were decreased in a high percentage of colorectal and breast tumor specimens. Right: TRIM21 protein levels were significantly decreased in colorectal and breast tumor specimens. (C) TRIM21 protein levels were significantly decreased in two additional cohorts of breast tumor specimens compared with nontumor breast tissues in TMAs, as analyzed by IHC staining. In A–C, TMAs were obtained from US Biomax. IHC scores were obtained as described in Methods. Data are shown as the mean ± SD. Statistical analysis was performed using 2-tailed unpaired Student’s t test. (D) Low TRIM21 mRNA expression is associated with poor progression-free survival in patients with mutp53 cancers. Kaplan-Meier survival analysis was employed. The survival information and TRIM21 expression z score relative to normal samples were obtained from cBioPortal. The patients were divided into low and high TRIM21 expression groups according to the cut-off of z score = 0. The difference between the two survival curves was analyzed using the log-rank (Mantel-Cox) test.